Navigation Links
S1 Biopharma Expands Focus to Include Male Sexual Health
Date:5/13/2012

JERSEY CITY, N.J., May 14, 2012 /PRNewswire/ -- S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD.

The expansion into male sexual health represents S1 Biopharma's intent to take a comprehensive and holistic approach to treating HSDD, a clinical condition marked by persistent lack of desire, personal distress, and interpersonal difficulty.

"In the case of couples with one or both partners experiencing HSDD, there is a benefit to treating both genders together rather than treating one partner alone," said Nicolas G. Sitchon, CEO of S1 Biopharma. "S1P-205 and Lorexys—our drug for female HSDD—are perfect for this dual treatment approach."

With the development of S1P-205, S1 Biopharma is taking steps to address desire disparity between partners and dispelling the myth than men don't have problems with desire.

Targeting Desire Dysfunction
Desire dysfunction in males remains underserved by the biopharma community, despite the fact that PDE-5 inhibitor therapies like Viagra have a 43% non-response rate[1] —a rate suggesting that psychogenic factors deserve more attention than they're currently receiving.

Diverse research exists to support this view of desire dysfunction in males. A study of over a hundred female nurses in a relationship with a male partner found that 29.5% reported having more desire than their male partner.[2] 

An earlier study of a representative sample of non-geriatric U.S. adults found that 10.2% of men had "trouble maintaining/achieving an erection", while 15% of the men in the study  experienced a problematic "lack of interest in sex."[3] Put differently, the incidence of desire dysfunction in this sample of men was nearly one and a half times the incidence of erectile dysfunction (ED).

"Lack of desire—rather than some cardiovascular or physiological pathology—is a medical condition that can play a significant role in male sexual disorders," said Robert E. Pyke, Chief Medical Officer of S1 Biopharma. "PDE-5 inhibitor therapies are only half the story, and we hope to address the other half with S1P-205, helping men and their partners to have more fulfilling relationships."

About S1 Biopharma, Inc.
S1 Biopharma (formerly S1 Pharmaceuticals) is an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions.  S1 Biopharma's lead product, Lorexys, is the only non-hormonal therapy for HSDD in women. The company is also developing S1P-205 as the first and only therapy for HSDD in men. For additional information, visit www.s1biopharma.com.

[1] Sildenafil U.S. Labeling, 2012

[2] Sand M and Fisher WA, Rethinking Desire: Prevalence and Correlates of Desire Discordance in the Nurses Sexuality Study, 2007

[3] Laumann EO and Michael RT, Sex, Love, and Health in America, Chicago, 2000

Contact:
press@s1biopharma.com


'/>"/>
SOURCE S1 Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
2. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
6. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
7. Equity Research on Most Popular Searches: Atmel, USG, Applied Materials, Sprint Nextel, Galena Biopharma, and Key Energy Services
8. PAREXEL Global Survey Results Identify Top Concerns of Biopharma Industry in Achieving Commercial Success
9. Pharmspective Announces the Release of ClearView™ - a New Health Care Reform Knowledge Management Web Application for the Biopharma Industry
10. PDL BioPharma Announces Conversion Rate Adjustments for Its Convertible Notes
11. Medtrack One View - A New More Powerful Biopharmaceutical Intelligence Tool Is Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... ... April 01, 2020 , ... As ... provider of urgent care and accessible primary care, launches its telemedicine platform, AFC/TeleCare, ... healthcare clinics will now provide virtual visits, allowing our medical providers to easily ...
(Date:3/30/2020)... , ... March 30, 2020 , ... ... its employees, today announced it has launched a series of survey question packs ... gather actionable feedback to inform mission-critical decisions. As the current situation continues to ...
(Date:3/30/2020)... ... 30, 2020 , ... Representatives with Miami-based Tattoo Vanish ... service. , "We are very excited to offer this service," said Barbara Gonzalez, ... Institute of Tattoo Removal is available to answer any questions or concerns regarding ...
Breaking Medicine Technology:
(Date:3/22/2020)... ... March 21, 2020 , ... The modular construction industry, led ... (MHBA), have been working with state and federal officials on ways to support ... use of modular construction to address the nation’s affordable housing crisis well before ...
(Date:3/22/2020)... , ... March 22, 2020 , ... “At a time ... do not feel well, Preferred Health Insurance Solutions’ First Stop Health Telemedicine program ... flu season underway, First Stop Health Telemedicine program, is a valuable tool that can ...
(Date:3/20/2020)... ... 20, 2020 , ... CommunityMed Urgent Care , based in Dallas, has ... room lets patients present online, complete registration paperwork (including the latest COVID screening) provide ... and get signaled that their clean exam room is ready. All of this ...
(Date:3/19/2020)... Denver, CO (PRWEB) , ... March 19, 2020 , ... ... and your family in this time of crisis. TOTR welcome new telepractice patients across ... team at info@therapiesotr.com or call 303-888-4840 to begin or resume your services safely! ...
(Date:3/19/2020)... ... ... As confirmed cases of COVID-19 rapidly increase in the United States, Project ... organization, Project HOPE’s mandate is always to respond where the need is greatest, and ... CEO of Project HOPE. “We will be supporting America’s health workers as they work ...
Breaking Medicine News(10 mins):